Every Form 4 that Day One Biopharmaceuticals, Inc. (DAWN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow DAWN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DAWN filings page.
Day One Biopharmaceuticals, Inc. insider entity AI Day1 LLC, a 10% owner, disposed of its entire position in connection with the company’s cash sale to Servier Detroit Inc. AI Day1 tendered 12,929,322 shares of Common Stock at $21.50 per share, all of which were accepted on April 23, 2026.
On the same date, each of AI Day1’s 827,586 pre-funded warrants to purchase Common Stock was converted into the right to receive $21.4999 in cash per warrant, leaving no remaining share or warrant holdings. The filing notes that these securities were held directly by AI Day1 and may be deemed beneficially owned by related Access Industries entities and Len Blavatnik, who each disclaim beneficial ownership beyond their pecuniary interest.
Day One Biopharmaceuticals, Inc. filed a Form 4 showing that Chief Executive Officer Jeremy Bender and related entities disposed of their equity in connection with the closing of the company’s cash merger with Servier. On April 23, 2026, each outstanding share of common stock was purchased or converted into the right to receive $21.50 per share in cash under the merger agreement. Various family trusts, including The Jeremy Bender 2023 Grantor Retained Annuity Trust and several Melissa Bender Grantor Retained Annuity Trusts, disposed of their Day One common shares to the issuer as part of the transaction. Bender’s directly held common stock, RSUs and stock options were also canceled and converted into cash based on the Merger Consideration, with options paid the difference between $21.50 and their exercise price. Following these issuer dispositions, the Form 4 shows zero shares and zero derivative awards remaining for the reported positions.
Day One Biopharmaceuticals executive Michael Vasconcelles disposed of all company equity holdings in connection with the closing of a cash merger. The filing shows that, upon the merger with Servier, each share of Common Stock was purchased or converted into the right to receive $21.50 in cash per share under the merger agreement.
Vasconcelles returned 4,397 Common shares to the issuer and all outstanding equity awards were canceled for cash. This included 106,875 and 226,000 Restricted Stock Units, and stock options for 171,000 and 346,000 shares with exercise prices of $11.16 and $6.64, respectively. Following these dispositions, his reported holdings in these securities are zero.
Day One Biopharmaceuticals’ COO and CFO, Charles N. York II, reported the cancellation of his equity due to the company’s merger with Servier. On April 23, 2026, each share of Day One common stock was cashed out at $21.50 per share under the merger terms.
York disposed of 312,025 shares of common stock in an issuer disposition, leaving him with zero reported common shares. His unvested stock options and restricted stock units first became fully vested and were then canceled at the merger’s effective time in exchange for cash equal to the merger consideration (or the merger price minus the option exercise price), less applicable taxes.
The filing shows multiple cancellations of RSUs and stock options covering hundreds of thousands of underlying shares, with all related derivative positions reported as 0 remaining after the merger.
Day One Biopharmaceuticals’ General Counsel & Secretary Adam Dubow disposed of all reported equity holdings in connection with the company’s cash merger. On the April 23, 2026 closing of the merger with Servier, each share of common stock was purchased or converted into the right to receive $21.50 in cash per share, subject to taxes.
The filing shows 72,694 shares of common stock and multiple grants of restricted stock units and stock options reported as dispositions to the issuer. Footnotes state that unvested stock options and RSUs became fully vested immediately before the merger, then were canceled for cash based on the $21.50 merger consideration (less the applicable exercise price for options). After these transactions, the form reports zero shares and zero derivatives remaining for the reporting person.
Day One Biopharmaceuticals director Natalie C. Holles reported the cash-out of all remaining equity awards in connection with the Servier acquisition. On April 23, 2026, her 57,310 shares of common stock, 15,000 restricted stock units, and multiple stock option grants were disposed of to the issuer at the merger closing.
Under the merger completed at an Offer Price of $21.50 per share, each common share was purchased or converted into the right to receive cash, and each stock option and RSU was canceled for a cash payment based on the merger consideration, less any required taxes. Following these transactions, the Form 4 shows no remaining common stock or derivative holdings for Holles.
Day One Biopharmaceuticals director Saira Ramasastry disposed of all reported equity interests in connection with the company’s cash merger with Servier. The filing shows 40,485 shares of Common Stock, 15,000 restricted stock units and multiple stock option grants were surrendered to the issuer on April 23, 2026.
Under the merger, each Day One share was purchased or converted into the right to receive $21.50 in cash, and each option or RSU was canceled for a cash payment based on this price, less any applicable exercise price and taxes. Following these transactions, the Form 4 lists no remaining shares or options for the reporting person.
Day One Biopharmaceuticals director John A. Josey disposed of his equity in connection with the company’s cash merger with Servier. Following the April 23, 2026 closing, his 72,292 shares of common stock were converted into cash at $21.50 per share under the merger terms.
His 15,000 restricted stock units and multiple fully vested stock option grants, covering tens of thousands of shares with exercise prices including $7.01 and $8.99, were canceled and converted into cash based on the merger consideration. After these issuer dispositions, the Form 4 shows no remaining common stock or derivative holdings.
Day One Biopharmaceuticals director Garland J. Scott reported dispositions of equity awards to the company in connection with its cash merger with Servier. On April 23, 2026, 15,000 restricted stock units and several stock option grants covering 22,500, 32,335, 37,500, 28,700 and 48,072 shares of common stock were disposed of to the issuer.
Under the merger, each common share was purchased or converted into the right to receive $21.50 in cash per share. At the merger’s effective time, all stock options and RSUs, which had become fully vested immediately beforehand, were canceled and converted into cash equal to the $21.50 merger consideration, or for options the $21.50 amount minus the applicable exercise price, less taxes.
Day One Biopharmaceuticals, Inc. director Habib J. Dable reports dispositions of equity awards back to the company tied to its cash merger. A completed merger with Servier entities converted Day One into a wholly owned subsidiary, with each common share purchased or converted for $21.50 per share in cash.
Immediately before the merger’s effective time, all unvested stock options and restricted stock units became fully vested. At closing, 15,000 RSUs and multiple stock option grants were canceled and converted into cash equal to the Merger Consideration, or for options the spread between $21.50 and each grant’s exercise price, less applicable taxes.
Day One Biopharmaceuticals director William Grossman reported the cancellation of equity awards in connection with the company’s cash merger with Servier entities. On April 23, 2026, he disposed to the issuer of 15,000 restricted stock units and three stock option grants covering 22,500, 32,335 and 66,660 shares of Common Stock.
Footnotes explain that, upon closing of the merger at $21.50 per share in cash, all outstanding unvested stock options and RSUs became fully vested, then each option and RSU was canceled and converted into the right to receive cash equal to the merger consideration (or, for options, the merger consideration minus the applicable exercise price), less withholding taxes. Following these transactions, the filing shows no remaining derivative holdings.
Day One Biopharmaceuticals director Garry A. Nicholson reported returning equity awards to the company in connection with its merger with Servier Pharmaceuticals LLC. On April 23, 2026, he disposed of 15,000 restricted stock units and multiple stock option grants back to the issuer.
Footnotes explain that, upon the merger closing at an offer price of $21.50 per share, all outstanding stock options and restricted stock units were fully vested, then canceled and converted into cash. For stock options, the cash amount equaled the difference between the $21.50 merger consideration and each option’s exercise price, less applicable taxes, leaving no remaining derivative holdings from these awards.
Day One Biopharmaceuticals, Inc. has been acquired by Servier under a merger that closed on April 23, 2026, with common stockholders receiving $21.50 per share in cash.
As part of the closing, Chief Commercial Officer Lauren Merendino disposed of 60,157 shares of common stock and all outstanding equity awards, including multiple restricted stock unit and stock option grants, through issuer dispositions. These awards were canceled and converted into cash based on the $21.50 per-share Merger Consideration, or, for options, the cash value of the spread over their exercise prices, less applicable taxes. Following these transactions, the filing shows Merendino with no remaining common shares or derivative equity holdings in the company.
Day One Biopharmaceuticals’ Chief Commercial Officer Lauren Merendino reported several equity transactions. On February 17, 2026, she sold 5,814 shares of common stock in an open-market sale at a weighted average price of $11.6009 per share, solely to cover tax liabilities from RSU settlements.
On February 15, 2026, multiple Restricted Stock Units converted into common stock at no cost, increasing her direct holdings. Footnotes state each RSU converts into one common share, does not expire, and vests in scheduled quarterly installments contingent on continued service.
Day One Biopharmaceuticals general counsel and secretary Adam Dubow reported an open-market sale of 6,395 shares of common stock at a weighted-average price of $11.6009, undertaken solely to cover his tax liability from the settlement of restricted stock units.
On February 15, several restricted stock unit (RSU) awards were settled into common stock at no cash cost, with each RSU delivering one share upon vesting. After these transactions, Dubow directly held 72,694 shares of common stock. The RSUs vest over time in quarterly installments, subject to his continued service.
Day One Biopharmaceuticals COO and CFO Charles N. York II reported a mix of stock sales and equity award settlements. He sold 6,065 shares of Common Stock in an open-market transaction at a weighted average price of $11.6009 per share. A footnote states this sale was solely to cover his tax liability arising from restricted stock unit (RSU) settlements.
On the same general timeline, he exercised and settled multiple RSU awards, each representing a right to receive one share of Common Stock for no cash consideration. The RSUs vest quarterly in 1/16th increments on February 15, May 15, August 15 and November 15, as long as he continues providing service to the company.
Day One Biopharmaceuticals, Inc. CEO Jeremy Bender reported a mix of RSU settlements and a tax-related share sale. On February 17, he sold 15,459 shares of common stock in an open-market transaction at a weighted average price of $11.6009 per share to cover tax liabilities from recently settled restricted stock units (RSUs).
Around February 15, multiple RSU awards were converted into common shares at no cash cost, reflecting equity compensation vesting. After these transactions, Bender directly held 204,603 shares of common stock, and additional shares are held indirectly through several Bender family and grantor retained annuity trusts. The RSUs vest in equal quarterly installments, so further scheduled vesting may occur if service continues.
Day One Biopharmaceuticals’ Head of Research and Development, Michael Vasconcelles, reported RSU vesting and a related share sale. On February 15, he acquired 7,125 shares of common stock at $0 per share through the settlement of Restricted Stock Units, each RSU converting into one common share.
On February 17, he conducted an open‑market sale of 2,728 common shares at a weighted average price of $11.6009 per share. The company notes that this sale was made solely to cover his tax liability arising from the RSU settlement and that the sale price reflects block trades executed within a range of $11.195 to $11.8508. After these transactions, he continued to hold common shares directly and retained a substantial RSU balance that vests quarterly, subject to continued service.
Day One Biopharmaceuticals granted new equity awards to its COO and CFO, Charles N. York II. On January 30, 2026, he received a stock option covering 188,000 shares of common stock at an exercise price of $11.16 per share, vesting in equal monthly installments over 48 months starting February 28, 2026.
He also received 126,000 Restricted Stock Units (RSUs), each representing one share of common stock upon settlement. These RSUs vest in 16 equal quarterly installments on February 15, May 15, August 15 and November 15, subject to continued service, and either vest or are canceled before vesting rather than expiring on a set date.
Day One Biopharmaceuticals granted new equity awards to its Head of Research and Development, Michael Vasconcelles, effective January 30, 2026. He received a stock option for 171,000 shares of common stock at an exercise price of $11.16, plus 114,000 Restricted Stock Units (RSUs).
The option vests as to 1/48 of the total shares each month starting February 28, 2026, contingent on continued service. Each RSU represents one share of common stock and vests 1/16 of the total award quarterly on February 15, May 15, August 15 and November 15, also subject to continued service. RSUs either vest or are canceled; they do not have an expiration date.
Day One Biopharmaceuticals reported new equity awards to its Chief Executive Officer Jeremy Bender. On January 30, 2026, he received a stock option for 355,000 shares of common stock at an exercise price of $11.16 per share, expiring on January 29, 2036. The option vests in equal monthly installments of 1/48th of the total from February 28, 2026, as long as he continues serving the company.
He was also granted 237,000 Restricted Stock Units (RSUs), each representing one share of common stock upon settlement. These RSUs vest in 1/16th increments on February 15, May 15, August 15 and November 15 in quarterly installments, contingent on continued service. The RSUs do not have a traditional expiration date; they either vest on schedule or are canceled if conditions are not met.
Day One Biopharmaceuticals granted its Chief Commercial Officer, Lauren Merendino, new equity awards dated January 30, 2026. She received a stock option for 110,000 shares of common stock at an exercise price of $11.16 per share. The option vests in 1/48th monthly, starting February 28, 2026, as long as she continues providing service on each vesting date.
Merendino also received 74,000 Restricted Stock Units (RSUs). Each RSU represents a right to one share of common stock upon settlement and vests in 1/16th quarterly installments on February 15, May 15, August 15 and November 15, subject to continued service. RSUs either vest or are canceled before the vesting date and do not have a traditional expiration date.
Day One Biopharmaceuticals’ General Counsel and Secretary, Adam Dubow, reported new equity awards. On January 30, 2026, he received a stock option for 105,000 shares of common stock at a $11.16 exercise price, held directly. The option vests in equal monthly installments over 48 months starting February 28, 2026, contingent on continued service.
He was also granted 70,000 Restricted Stock Units (RSUs), each representing one share of common stock upon settlement. The RSUs vest in 16 quarterly installments on February 15, May 15, August 15, and November 15, subject to ongoing service, and either vest or are canceled before vesting.
Day One Biopharmaceuticals (DAWN) CEO and director reported multiple internal transfers of common stock among family trusts on 11/25/2025. The Form 4 shows several code G transactions at a price of $0 per share, including transfers of 300,000 shares of common stock from the Bender Revocable Trust to the Jeremy Bender 2025 Grantor Retained Annuity Trust and to the Melissa Bender 2025 Grantor Retained Annuity Trust.
Additional movements involved 7,225 shares held by the Jeremy Bender 2022 Grantor Retained Annuity Trust, which decreased to zero after the reported transaction. Following these changes, the Bender Revocable Trust held 808,285 shares, while the various 2022 and 2023 Grantor Retained Annuity Trusts for Jeremy and Melissa Bender collectively held multiple indirect positions, including 177,165, 20,204, 147,702, and 18,197 shares of common stock. No derivative securities were reported.
Day One Biopharmaceuticals (DAWN) reported insider equity activity by its General Counsel & Secretary. On November 15, 2025, several blocks of Restricted Stock Units (RSUs) were settled, delivering 2,963, 1,750, and two blocks of 3,687 shares of common stock, each RSU converting into one share for no cash consideration. The RSUs vest over time based on continued service, with portions vesting on specified quarterly dates.
On November 17, 2025, the insider sold 4,319 shares of common stock at a weighted average price of $8.9147 per share, solely to cover tax liabilities related to the RSU settlements. After these transactions, the insider beneficially owned 62,626 shares of Day One common stock directly.
Day One Biopharmaceuticals, Inc. insider and COO and CFO Charles N. York II reported the settlement of restricted stock units (RSUs) and a related sale of common stock. On 11/15/2025, multiple RSU awards were exercised, delivering blocks of 1,375, 2,250 and 6,625 shares of common stock in several transactions. Following these issuances, he held up to 298,777 shares of common stock before a subsequent sale.
On 11/17/2025, he sold 4,062 shares of common stock at a weighted average price of $8.9147 per share, with actual prices ranging from $8.545 to $9.305. The sale is stated to be solely to cover his tax liability arising from the RSU settlements. After the transactions, he directly owned 294,715 shares of common stock and held 79,500 RSUs, each representing a right to receive one share of common stock upon vesting.
Day One Biopharmaceuticals (DAWN) reported insider equity activity by its Chief Commercial Officer on a Form 4. On 11/15/2025, several batches of Restricted Stock Units (RSUs) converted into a total of 10,536 shares of common stock through multiple transactions coded "M". Following these RSU settlements, the officer beneficially owned 54,535 shares of common stock directly.
On 11/17/2025, the officer sold 3,726 shares of common stock in a transaction coded "S" at a weighted average price of $8.9147 per share, as part of block trades executed in a price range from $8.545 to $9.305. The filing states that this sale was made solely to cover tax liabilities arising from the RSU settlements. The RSUs vest in quarterly installments over time, subject to continued service, and do not have an expiration date.
Day One Biopharmaceuticals (DAWN) CEO Jeremy Bender reported routine equity transactions. On 11/15/2025, multiple Restricted Stock Units (RSUs) were settled into a total of 31,694 shares of common stock in four separate transactions (3,570; 4,750; 11,687; 11,687 shares). Each RSU represents a right to receive one share of common stock for no cash consideration.
On 11/17/2025, Bender sold 15,894 shares of common stock at a weighted average price of $8.9147 per share, with prices ranging from $8.545 to $9.305. The filing states this sale was made solely to cover tax liabilities arising from the RSU settlements. After these transactions, he directly holds 177,165 shares of common stock, with additional indirect holdings through several Bender family trusts.
Day One Biopharmaceuticals (DAWN): Director Form 4 discloses option repricing. On 11/06/2025, two stock option grants were repriced to an exercise price of $8.99, equal to the Nasdaq closing price on the effective date if lower than the original price.
The actions replaced options for 66,660 shares at $13.81 and 32,335 shares at $13.87 with new options at $8.99. To exercise the repriced options, the reporting person must remain in service through the Retention Period, ending on the earlier of the 12‑month anniversary of the effective date or a Corporate Transaction. One grant vests 1/36 monthly beginning 02/17/2024; the other is fully vested.
Day One Biopharmaceuticals (DAWN) reported a Form 4 showing an option repricing for its Chief Executive Officer effective November 6, 2025, following Board approval on October 7, 2025. The affected stock options were reset to a new exercise price of $8.99, the Nasdaq closing price on the effective date, with no change to other terms.
Affected grants include options previously priced at $16.00 (covering 1,463,134 shares), $14.26 (397,000 shares), $23.41 (244,000 shares), and $14.44 (286,000 shares). One grant is fully vested; others vest monthly per their original schedules.
Exercising the repriced options at $8.99 requires the CEO to remain in service through the defined Retention Period, which ends on the earlier of the 12‑month anniversary of the effective date or a Corporate Transaction. The transactions were reported as exempt under Rule 16b‑6(d) and Rule 16b‑3.
Day One Biopharmaceuticals (DAWN) filed a Form 4 showing an option repricing for a director. On 11/06/2025, fully vested stock options were repriced to an exercise price of $8.99, replacing prior grants with higher strike prices while keeping original terms and expirations. The transactions include exchanges of 63,000 (from $16; expiring 05/25/2031), 1,181 (from $16; 05/25/2031), 28,700 (from $16.29; 06/20/2032), 37,500 (from $12.69; 06/21/2033), and 32,335 (from $13.87; 05/22/2034) options, each reacquired at $8.99. The board approved the repricing on 10/07/2025. Exercising at the new price requires service through a “Retention Period” that ends on the earliest of the 12‑month anniversary of the effective date or a Corporate Transaction; other terms remain unchanged.
Day One Biopharmaceuticals (DAWN) disclosed a director’s option repricing on a Form 4. The Board approved the action on October 7, 2025, and it became effective on November 6, 2025. Previously granted stock options with exercise prices of $16.00, $16.29, $12.69, and $13.87 were disposed and replaced with options at a new exercise price of $8.99.
The repriced grants cover 40,000, 40,300, 28,700, 37,500, and 32,335 underlying shares, respectively, and are reported as directly owned. The options are fully vested. To exercise at the new price, the reporting person must remain in service through the “Retention Period,” which ends at the earlier of the 12‑month anniversary of the effective date or a Corporate Transaction; the footnotes note an exception related to death or Disability under the company’s 2021 Equity Incentive Plan. The transactions were exempt under Rules 16b‑6(d) and 16b‑3.
Day One Biopharmaceuticals (DAWN) filed a Form 4 reporting an option repricing for a director. On 11/06/2025, previously granted stock options with exercise prices of $25.84 (33,900 shares), $12.69 (37,500 shares), and $13.87 (32,335 shares) were replaced with options at a new exercise price of $8.99, matching the Nasdaq closing price on the effective date. The Board approved the repricing on 10/07/2025.
The options are fully vested. To exercise at the new price, the reporting person must remain in service through the “Retention Period,” which ends at the earlier of the 12-month anniversary of 11/06/2025 or a Corporate Transaction, with certain exceptions for death or Disability as defined in the company’s 2021 plan.
Day One Biopharmaceuticals (DAWN) director filed a Form 4 reporting an option repricing approved on Oct 7, 2025 and effective Nov 6, 2025. The exercise price for certain fully vested stock options was reset to $8.99, the Nasdaq closing price on the effective date.
The repriced grants cover 48,072 options (from $24.65; expiring Aug 15, 2031), 28,700 (from $16.29; expiring Jun 20, 2032), 37,500 (from $12.69; expiring Jun 21, 2033), and 32,335 (from $13.87; expiring May 22, 2034). All other terms remain unchanged.
Exercising at the new price requires service through the Retention Period, which runs from Nov 6, 2025 until the earlier of the 12-month anniversary or a Corporate Transaction, with specified exceptions for death or Disability.
Day One Biopharmaceuticals (DAWN): Form 4 discloses option repricing by a director. On 11/06/2025, previously granted and fully vested stock options with exercise prices ranging from $12.69 to $16.29 were canceled and replaced at a new exercise price of $8.99, the Nasdaq closing price on the effective date.
The repriced grants cover multiple tranches with original expirations unchanged (ranging from 05/25/2031 to 05/22/2034). Exercising at the new price requires service through the “Retention Period,” which ends on the earlier of 12 months from the effective date or a Corporate Transaction, with specified exceptions. The transactions were exempt under Rule 16b-6(d) and Rule 16b-3.
Day One Biopharmaceuticals (DAWN) filed a Form 4 showing an option repricing for its COO and CFO. On November 6, 2025, multiple stock option grants held by the reporting person were repriced to an exercise price of $8.99 if lower than the original price, following a Board approval on October 7, 2025.
The filing lists prior grants adjusted from higher strikes, including 497,667 underlying shares previously at $16 (fully vested), 151,000 at $14.26, 116,000 at $23.41, 162,000 at $14.44, and 162,000 at $11.87. The revised entries show corresponding grants at $8.99 with the same underlying share counts. Vesting terms remain unchanged, such as 2.0833% monthly with full vest by January 18, 2026, and multiple 1/48th monthly schedules starting on specified dates.
To exercise at the new price, continued service is required through the “Retention Period,” which runs from the effective date until the earlier of 12 months or a Corporate Transaction, with an exception for death or Disability under the plan.
Day One Biopharmaceuticals (DAWN) filed a Form 4 for its General Counsel & Secretary. On 11/06/2025, the officer was granted a stock option for 309,000 shares at an exercise price of $8.99, vesting 100% on November 6, 2026.
The filing also records an option repricing approved on October 7, 2025 and effective November 6, 2025: three existing options covering 90,000 shares each were canceled at prior exercise prices of $23.41, $14.44, and $11.87 and replaced with options at $8.99, keeping original expirations in 2033–2035 and monthly vesting schedules. To exercise at the new price, service through the Retention Period is required, which ends at the earlier of the 12‑month anniversary of the Effective Date or a Corporate Transaction.
Day One Biopharmaceuticals (DAWN) reported a director’s Form 4 reflecting an option repricing effective November 6, 2025. Existing stock options were reset to a new exercise price of $8.99, the Nasdaq closing price on the effective date.
The filing shows dispositions of options previously priced at $13.81 (66,660 shares; expiring 01/16/2034) and $13.87 (32,335 shares; expiring 05/22/2034), and corresponding acquisitions of options for the same share amounts at $8.99 with the same expiration dates. One grant vests 1/36 monthly beginning February 17, 2024; the other is fully vested. Exercising at the new price requires continued service through a defined Retention Period, and the transactions were noted as exempt under Rule 16b-6(d) and Rule 16b-3.
Day One Biopharmaceuticals (DAWN) filed a Form 4 reporting an option repricing for its Chief Commercial Officer. On November 6, 2025, certain stock options were repriced to a new exercise price of $8.99, equal to the Nasdaq closing price on the effective date.
The transactions replaced prior exercise prices for options covering 330,200 shares (originally $12.54, expiring 06/11/2033), 90,000 shares (originally $14.44, expiring 01/04/2034), and 90,000 shares (originally $11.87, expiring 01/14/2035). All other terms remain unchanged. To exercise at $8.99, the reporting person must remain in service through the Retention Period, which ends on the earliest of the 12‑month anniversary of the effective date or a Corporate Transaction; the additional premium is waived upon death or disability.
Vesting continues as previously set: 25% on June 12, 2024 with monthly vesting thereafter through June 12, 2027 for the 330,200‑share grant; and 1/48th monthly starting February 5, 2024 and February 15, 2025 for the two 90,000‑share grants. The issuer states these transactions are exempt under Rule 16b‑6(d) and Rule 16b‑3.